Seeking Alpha Bullish on Novo Nordisk After Q3, But Risks Remain

What happened

The Seeking Alpha article rates NVO a buy with a target price of $57.24, citing Q3 results that show Wegovy Pill sales surged 53% and drove net patient additions, arguing the oral form expands the market rather than cannibalizing injectables. The master report, however, remains more cautious, rating potential buy with a base value of $46, noting that Q3 operating profit still fell 9% due to non-cash impairments and that the upcoming 2027 price reset and Lilly competition pose risks. While the article highlights moderating capex and expanding free cash flow as a margin of safety, the master report sees financial resilience but not a wide strategic moat, with downside to $32 if price cuts fail to boost volumes. The article's bullish thesis aligns with the master's bull case of $56, which assumes CagriSema launch and continued oral momentum, but that scenario is only 25% likely. Overall, the news does not change the fundamental setup but adds a more optimistic interpretation of the same data.

Implication

The article's claim that cannibalization is disproven may be premature because the surge in oral sales could still cannibalize injectables over time, especially as payers and patients shift to cheaper oral options. The master report's central scenario values NVO at $46, implying about 14% upside from current levels, not the 34% suggested by the article, reflecting continued pricing and competitive risks. The January 2027 price reset to $675 for Wegovy will be a critical test: if volume does not accelerate enough to offset lower net pricing, the bear case of $32 becomes more plausible. Conversely, successful CagriSema launch and durable oral adoption could move the stock toward the bull case of $56, but that is not the base. Therefore, investors should maintain a cautious position, monitoring refill durability, price elasticity, and pipeline milestones rather than chasing the article's target.

Thesis delta

The article provides an aggressive bull perspective that is plausible but not yet proven. The master thesis remains 'potential buy' with balanced scenario weights; the article's arguments increase confidence in the bull case but do not eliminate downside risks. No material change to the core thesis; the stock is still a wait-and-see on price elasticity and pipeline.